Defense Secretary Pete Hegseth has ordered annual testosterone-deficiency screening for all active-duty and reserve personnel aged 30 and older. Testing will become part of the military’s Periodic Health Assessment, while younger service members may request it voluntarily. Hegseth says any resulting testosterone replacement therapy will remain optional.

The July 15 Pentagon memorandum declares the requirement effective immediately and calls for implementing guidance by August 15. Hegseth has promoted the initiative as part of a “High-T Department of War” intended to keep troops on the “leading edge of lethality.”

That branding is certainly memorable. Whether it represents sound military medicine or a medical policy dressed up for social media is the question.

A Readiness Problem Supporters Believe Deserves Attention

Testosterone Can Affect Military Performance

The basic medical premise behind Hegseth’s initiative isn’t imaginary. Testosterone contributes to muscle mass, bone strength, red-blood-cell production, sexual function, mood, and general physical health. A genuine deficiency can be associated with reduced strength, fatigue, depression, anemia, diminished bone density, and other problems that could affect a service member’s health and performance.

The military isn’t an ordinary workplace. Service members may be expected to carry heavy equipment, operate on limited sleep, endure extreme temperatures, recover from traumatic injuries, and remain psychologically alert under prolonged stress. A medical condition that might merely inconvenience someone working behind a desk could become a genuine readiness issue in a combat environment.

Supporters therefore argue that waiting for severe symptoms to appear isn’t necessarily the wisest approach. If the military routinely monitors vision, hearing, body composition, cardiovascular health, and other readiness indicators, adding another relevant biomarker may appear reasonable.

Screening Could Identify More Than a Hormone Problem

An abnormally low testosterone result doesn’t always mean that someone needs testosterone therapy. It can point toward obesity, chronic illness, pituitary dysfunction, testicular injury, traumatic brain injury, medication effects, inadequate nutrition, or persistent sleep disruption.

Viewed that way, screening could function as an early-warning system. A low result might lead physicians to uncover a treatable underlying condition before it becomes a larger medical or operational problem.

That possibility may be particularly relevant among reservists, whose health and fitness aren’t managed as continuously as those of full-time active-duty personnel. Supporters contend that a yearly screening could catch problems that otherwise remain undiagnosed until mobilization or deployment.

Military Conditions May Justify Different Standards

Most medical organizations advise against routine testosterone screening in the general population when patients lack symptoms. Supporters answer that combat personnel aren’t the general population.

The Pentagon specifically links the program to “Operator Syndrome,” a combination of traumatic brain injury, hormonal disturbances, sleep problems, chronic pain, psychological stress, and metabolic dysfunction observed among some special-operations veterans. Those personnel experience extraordinary physical and neurological demands, and hormonal evaluation may be appropriate as part of their treatment.

The argument for expanding screening is that less-specialized troops can also experience blast exposure, sleep deprivation, chronic stress, traumatic injuries, and extreme energy deficits. A standard designed exclusively around relatively sedentary civilians might therefore miss problems relevant to military service.

Supporters don’t necessarily claim that every 30-year-old with a low reading needs medication. They argue that it’s useful to know the reading, investigate the cause, and allow a physician and service member to decide what should happen next.

Treatment Is Supposed to Remain Voluntary

The distinction between screening and treatment is important. Hegseth has said that personnel won’t be required to receive testosterone replacement therapy simply because testing reveals a low level.

The memorandum also directs the Defense Health Agency to develop clinical decision support, educate medical personnel, and establish an advisory council containing outside experts. If implemented carefully, those protections could prevent one abnormal result from turning into an automatic prescription.

Supporters also point to evolving evidence about testosterone therapy. In June 2026, the FDA requested the removal of an earlier labeling limitation concerning age-related hypogonadism after reviewing newer research. The large TRAVERSE trial didn’t find a meaningful increase in major cardiovascular events among the men studied, although other risks and uncertainties remain. HHS described the change as an effort to bring product labeling into line with newer evidence.

From this perspective, the initiative could offer legitimate care to personnel who have a confirmed deficiency rather than encouraging illicit use of anabolic steroids or unregulated supplements.

A Force-Wide Program Could Produce Valuable Data

Military medicine has a long history of generating health information that benefits both service members and civilians. Standardized testing could help researchers understand how combat exposure, age, sleep, injury, obesity, deployment schedules, and occupational specialties affect hormonal health.

The data could also reveal whether testosterone screening has different implications for male and female personnel. The directive applies to “all” covered personnel, but the Pentagon hasn’t yet explained how sex-specific reference ranges, diagnoses, and treatment protocols will be handled.

Supporters see that uncertainty as a reason to develop the program carefully, not abandon it before useful information can be gathered.

Why Critics See a Premature Medical Mandate

Screening Healthy People Isn’t the Same as Treating Patients

The strongest objection isn’t that testosterone deficiency is unimportant. It’s that force-wide screening of people without symptoms departs from established clinical practice.

The Endocrine Society recommends against routine population screening, while current Veterans Health Administration guidance says evaluation should generally be limited to men with relevant symptoms, findings, or risk factors. The VA also warns that obesity, caloric deficiency, opioid use, acute illness, and other conditions can temporarily suppress testosterone levels. Its guidance calls for early-morning testing on at least two separate occasions before a diagnosis is confirmed. The VA’s January 2026 recommendations are considerably more detailed than the Pentagon’s one-page directive.

That matters because testosterone isn’t like a serial number stamped permanently onto the body. Levels fluctuate according to time of day, stress, sleep, illness, nutrition, medications, and laboratory methods. A tired service member tested after night duty, strenuous training, or inadequate food could produce a low result that says more about the previous 48 hours than about an endocrine disorder.

Without strict testing procedures, the program risks generating a large number of misleading results.

The Age of 30 Appears Arbitrary

Testosterone levels often begin declining gradually sometime after age 30 or 40, but normal aging isn’t itself a disease. Individuals vary considerably, and clinically significant deficiency remains relatively uncommon among otherwise healthy younger men.

Most major testosterone-treatment trials have involved older, symptomatic men. The TRAVERSE trial, for example, studied men between 45 and 80 who had low testosterone and existing cardiovascular risks. That doesn’t establish that annual screening beginning at age 30 will improve combat effectiveness across the entire force.

In other words, the policy takes evidence developed primarily from older, symptomatic patients and stretches it into a mandate for hundreds of thousands of younger, frequently asymptomatic people. That’s a substantial leap, and the Pentagon hasn’t publicly shown the bridge.

A Low Number Can Lead to Unnecessary Treatment

Hegseth says treatment will be voluntary, but medical screening creates momentum. Once a test labels someone “deficient,” the service member may understandably believe that treatment is needed, even if the result reflects sleep deprivation, weight, stress, illness, or inadequate nutrition.

Testosterone therapy can suppress natural hormone production and sperm formation, potentially causing infertility. It can also increase red-blood-cell concentration, raise blood pressure, and require monitoring for prostate and cardiovascular concerns. The VA recommends continuing treatment only when it produces meaningful, sustained improvement in symptoms.

Even the evidence concerning benefits is less dramatic than the “leading edge of lethality” language suggests. The VA’s review reports only modest average improvements in physical-function testing among older men and no meaningful improvement on one major fatigue measure. It also notes increased clinical fractures in a TRAVERSE sub-study.

Testosterone can be valuable medicine for the right patient. That doesn’t make it liquid courage, injectable discipline, or Captain America serum.

The Policy May Treat the Measurement Instead of the Cause

Military life itself can reduce testosterone through chronic sleep deprivation, overtraining, inadequate recovery, traumatic brain injury, stress, and caloric deficit. If those institutional conditions are producing abnormal hormone levels, giving troops another annual blood test may document the problem without solving it.

A service member who sleeps four hours a night because of duty schedules doesn’t necessarily need a hormone prescription. He may need sleep. Someone whose levels are suppressed by poor nutrition may need better food and recovery time. A person suffering from brain trauma needs a comprehensive neurological and endocrine evaluation, not a catchy slogan and a syringe.

Critics therefore argue that the Pentagon should first address the conditions driving hormonal disruption. Otherwise, the program could become the medical equivalent of disconnecting the dashboard warning light because repairing the engine is inconvenient.

Cost, Privacy, and Career Consequences Remain Unclear

The Pentagon hasn’t publicly explained the projected cost, testing method, diagnostic threshold, confirmatory process, or implications for deployability. Nor has it clearly said whether a service member who refuses recommended treatment could face duty restrictions or career consequences.

Mandatory screening creates sensitive medical information. Troops need to know who can access it, how it will affect assignments, and whether an abnormal result might become an unofficial measure of fitness or masculinity.

The phrase “High-T Department of War” doesn’t help. It invites the impression that testosterone level is being treated as a scoreboard for manhood rather than one medical measurement among many. A highly capable pilot, intelligence analyst, cyber specialist, physician, or infantry officer can’t be reduced to a number on a hormone panel.

The Political Messaging Creates Additional Questions

Democratic critics have accused Hegseth of inconsistency because his department is willing to provide hormone treatment for testosterone deficiency while excluding transgender personnel who may use hormone therapy.

Supporters respond that restoring a person’s natural hormone levels and administering hormones to produce opposite-sex characteristics are medically and conceptually different treatments. Nevertheless, critics argue that the administration appears to celebrate hormone therapy when it reinforces its preferred image of masculinity while condemning it in another setting.

Even apart from the transgender debate, the branding makes the policy look more ideological than clinical. Medical decisions require sober standards, careful diagnosis, and informed consent. Chest-thumping hashtags are generally not included in the Hippocratic oath.

A Legitimate Concern Wrapped in a Premature Mandate

I would argue that Hegseth has identified a real issue but chosen an approach that’s broader, faster, and more theatrical than the available evidence appears to justify.

We shouldn’t mock men’s health. Testosterone deficiency can seriously affect physical strength, emotional well-being, fertility, bone health, and quality of life. Service members exposed to traumatic brain injuries, chronic sleep deprivation, extreme stress, or punishing operational schedules deserve attentive medical care. The nation has a moral obligation to care for the people it places in harm’s way, not use them until they break and then thank them with a form letter.

There’s also nothing inherently wrong with testosterone replacement therapy when it’s used to treat a genuine deficiency under proper medical supervision. Restoring a man’s physiology to a healthy range isn’t morally or medically equivalent to using cross-sex hormones to alter healthy sexual characteristics. Critics may dislike that distinction, but disliking a distinction doesn’t make it disappear.

Still, a commitment to military strength should be accompanied by prudence, fiscal accountability, individual dignity, and respect for medical evidence. The government shouldn’t impose force-wide testing simply because a health marker sounds rugged in a promotional video. Biblical manhood is measured by courage, faithfulness, self-control, integrity, sacrifice, and responsibility, not nanograms per deciliter. A laboratory report isn’t a certificate of valor.

The Pentagon should begin with a controlled pilot involving personnel who have relevant symptoms, traumatic brain injuries, chronic sleep disruption, opioid exposure, infertility concerns, or unusually demanding combat occupations. Any abnormal result should be confirmed through at least two properly timed morning tests. Clinicians should investigate sleep, nutrition, weight, medication use, illness, and injury before recommending hormone therapy. Fertility risks must be explained plainly, medical information must be protected, and declining treatment must not quietly become a career penalty.

The department should also establish sex-specific protocols, publish cost and readiness outcomes, and demonstrate that screening actually improves deployability, retention, injury rates, or performance before making annual testing permanent across the entire force.

So, my verdict is neither “Hegseth is crazy” nor “More testosterone automatically means more military.” The medical concern is legitimate, and targeted screening could benefit some service members. But the current blanket mandate gets ahead of the evidence and risks turning a serious health issue into another culture-war mascot.

Keep the concern. Lose some of the swagger. Test the program before using the entire military to test the theory.